Ferrous Sulfate Switched with Meclizine HCl, Recalled Nationwide

En Español

On January 17, 2013, Advance Pharmaceutical Inc. issued a nationwide recall on Ferrous Sulfate Tablets, 325 mg, Lot 12G468.

The recall was initiated in December when a pharmacist brought to the company’s attention that a bottle of Ferrous Sulfate Tablets, 325 mg 07-2014, actually contained Meclizine HCl 25 mg tablets, NDC 0536-3990-01. Ferrous Sulfate is used to treat anemia, by increasing levels of iron in the blood. Meclizine HCl, however, is a self-administered drug used to treat motion sickness and symptoms of vertigo.

The FDA stated that accidental doses of Meclizine HCl could cause serious side-effects if combined with alcohol or other sedatives or if taken by elderly patients, patients with CNS disorder and patients with impaired kidney or liver function. Meclizine HCl could also cause adverse side-effects in infants of women who have received the drug during pregnancy or breastfeeding.

Consumers who take the 3 tablets of the wrongly-labeled medication will be inadvertently taking 75 mg, nearly the maximum daily dose of Meclizine HCl. A consistent triple dose of this drug on a daily basis is likely to cause Meclizine HCl toxicity which could lead to serious adverse side effects including:

• impaired alertness
• drowsiness
• confusion
• low blood pressure
• coma
• respiratory depression

Without adequate timely treatment, Meclizine HCl toxicity can be fatal.

Consumers who believe they may have been affected by the Ferrous Sulfate recall are advised to contact Advance Pharmaceutical Inc.

If you are a patient requiring legal assistance due to adverse side-effects relating to the Ferrous Sulfate recall, please use the form to contact our attorneys. We can get you the help you need.